Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations
What are the risks if subsequent validation studies do not confirm the assay's performance?
Could the assay's ability to monitor multiple targetable mutations lead to broader applications beyond leptomeningeal metastases?
What are the potential reimbursement challenges for the CNSide assay in key markets?
10 days ago